search
Back to results

Expanded Access to NanoDoce

Primary Purpose

Urogenital Neoplasms

Status
Available
Phase
Locations
Study Type
Expanded Access
Intervention
NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension
Sponsored by
NanOlogy, LLC
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an expanded access trial for Urogenital Neoplasms

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)

Inclusion Criteria:

-

Exclusion Criteria:

-

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    August 14, 2019
    Last Updated
    April 7, 2022
    Sponsor
    NanOlogy, LLC
    Collaborators
    US Biotest, Inc.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04060628
    Brief Title
    Expanded Access to NanoDoce
    Official Title
    Expanded Access to NanoDoce
    Study Type
    Expanded Access

    2. Study Status

    Record Verification Date
    April 2022
    Overall Recruitment Status
    Available
    Study Start Date
    undefined (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    NanOlogy, LLC
    Collaborators
    US Biotest, Inc.

    4. Oversight

    5. Study Description

    Brief Summary
    NanOlogy may consider offering expanded access to NanoDoce for patients who do not meet the enrollment criteria of clinical trials in progress.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Urogenital Neoplasms

    7. Study Design

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension
    Other Intervention Name(s)
    docetaxel

    10. Eligibility

    Eligibility Criteria
    Inclusion Criteria: - Exclusion Criteria: -
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Gere diZerega, MD
    Phone
    805-595-1300
    Email
    gere.dizerega@usbiotest.com

    12. IPD Sharing Statement

    Learn more about this trial

    Expanded Access to NanoDoce

    We'll reach out to this number within 24 hrs